Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils.


Journal

Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472

Informations de publication

Date de publication:
01 06 2023
Historique:
received: 28 10 2022
revised: 27 03 2023
accepted: 03 05 2023
medline: 5 6 2023
pubmed: 3 6 2023
entrez: 2 6 2023
Statut: ppublish

Résumé

Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2, affects human neutrophil development and function. TET2 loss in hHSCs produce a distinct neutrophil heterogeneity in bone marrow and peripheral tissues by increasing the repopulating capacity of neutrophil progenitors and giving rise to low-granule neutrophils. Human neutrophils that inherited TET2 mutations mount exacerbated inflammatory responses and have more condensed chromatin, which correlates with compact neutrophil extracellular trap (NET) production. We expose here physiological abnormalities that may inform future strategies to detect TET2-CH and prevent NET-mediated pathologies associated with CH.

Identifiants

pubmed: 37267914
pii: S1934-5909(23)00174-1
doi: 10.1016/j.stem.2023.05.004
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins 0
TET2 protein, human EC 1.13.11.-
DNA-Binding Proteins 0
Dioxygenases EC 1.13.11.-
Tet2 protein, mouse EC 1.13.11.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

781-799.e9

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Hector Huerga Encabo (H)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: hector.encabo@crick.ac.uk.

Iker Valle Aramburu (IV)

Laboratory of Antimicrobial Defence, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Manuel Garcia-Albornoz (M)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Marion Piganeau (M)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Henry Wood (H)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Anna Song (A)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Alessandra Ferrelli (A)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Aneesh Sharma (A)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Carlos M Minutti (CM)

Immunobiology Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Marie-Charlotte Domart (MC)

Electron Microscopy Science Technology Platform, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Despoina Papazoglou (D)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Kristian Gurashi (K)

Division of Cancer Sciences, The University of Manchester, Manchester, UK.

Miriam Llorian Sopena (M)

Bioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Robert Goldstone (R)

Bioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Todd Fallesen (T)

Advanced Light Microscopy Science Technology Platform, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Qian Wang (Q)

Laboratory of Antimicrobial Defence, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Linda Ariza-McNaughton (L)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Daniel H Wiseman (DH)

Division of Cancer Sciences, The University of Manchester, Manchester, UK.

Kiran Batta (K)

Division of Cancer Sciences, The University of Manchester, Manchester, UK.

Rajeev Gupta (R)

Haematology Stem Cell Group, UCL Cancer Institute, London, UK.

Venizelos Papayannopoulos (V)

Laboratory of Antimicrobial Defence, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: veni.papayannopoulos@crick.ac.uk.

Dominique Bonnet (D)

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: dominique.bonnet@crick.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH